Dopamine transporter availability in medication free and in bupropion treated depression: A 99mTc-TRODAT-1 SPECT study

Bupropion is thought to exert its antidepressive effect by blocking the dopamine transporter (DAT). The purpose of this study was to evaluate the DAT activity in depressed patients by means of 99mTc-TRODAT-1 SPECT in relation to the efficacy of bupropion treatment. In 12 healthy controls and 16 depr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of affective disorders 2005-12, Vol.89 (1), p.115-123
Main Authors: Árgyelán, Miklós, Szabó, Zoltán, Kanyó, Balázs, Tanács, Attila, Kovács, Zsuzsanna, Janka, Zoltán, Pávics, László
Format: Article
Language:English
Subjects:
Adult
Adult and adolescent clinical studies
Antidepressive Agents, Second-Generation - therapeutic use
Biological and medical sciences
Bupropion
Bupropion - therapeutic use
Corpus Striatum - diagnostic imaging
Corpus Striatum - drug effects
DAT
Depression
Depressive Disorder - diagnostic imaging
Depressive Disorder - drug therapy
Dopamine Plasma Membrane Transport Proteins - drug effects
Dopamine Uptake Inhibitors - therapeutic use
Female
Humans
Male
Medical sciences
Middle Aged
Mood disorders
Neuropharmacology
Occipital Lobe - diagnostic imaging
Occipital Lobe - drug effects
Occupancy
Organotechnetium Compounds
Personality Inventory
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Reference Values
SPECT
Statistics as Topic
Tomography, Emission-Computed, Single-Photon
Treatment Outcome
TRODAT-1
Tropanes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bupropion is thought to exert its antidepressive effect by blocking the dopamine transporter (DAT). The purpose of this study was to evaluate the DAT activity in depressed patients by means of 99mTc-TRODAT-1 SPECT in relation to the efficacy of bupropion treatment. In 12 healthy controls and 16 depressed patients the baseline DAT activity was examined. Nine of the 16 patients went through an additional second SPECT investigation, after 4 weeks of bupropion treatment. In the depressed patients, the baseline DAT striatum–occipital ratio (SOR) (1.04 ± .36, mean ± SD) was not significantly different from that in the control group (1.12 ± .33) ( p > .05). Correlation was found between baseline SOR and HAM-D score change ( r = − .745, p = .02) of the bupropion treated patients. The average DAT occupancy due to the bupropion treatment was 20.84 ± 27.7%. No significant correlation between the therapeutical effectiveness and the occupancy was observed. One of the limiting factors of our study has been the lack of drug monitoring. In good agreement with other PET studies, we found 20.84% DAT occupancy during bupropion treatment. The lack of correlation between the efficacy of therapy and occupancy of DAT may raise the question as to whether other mechanisms are involved in the effect of bupropion.
ISSN:0165-0327
1573-2517
DOI:10.1016/j.jad.2005.08.016